Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study (Q36607690)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

6 March 2020

main subject

0 references

author

Yohann Foucher

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Pierre Clavelou

15

1 reference

ORCID Public Data File 2021

author name string

Laetitia Barbin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Chloe Rousseau

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Natacha Jousset

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Romain Casey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Marc Debouverie

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Sandra Vukusic

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Jerome De Sèze

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

David Brassat

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Sandrine Wiertlewski

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Bruno Brochet

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Jean Pelletier

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Patrick Vermersch

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Gilles Edan

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Christine Lebrun-Frenay

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Eric Thouvenot

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Jean-Philippe Camdessanché

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Ayman Tourbah

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Bruno Stankoff

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Abdullatif Al Khedr

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Philippe Cabre

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Caroline Papeix

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Eric Berger

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Olivier Heinzlef

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Thomas Debroucker

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Thibault Moreau

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Olivier Gout

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Bertrand Bourre

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Alain Créange

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Pierre Labauge

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Laurent Magy

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Gilles Defer

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

David A Laplaud

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

CFSEP and OFSEP groups

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

language of work or name

English

0 references

publication date

29 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

771-778

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

6 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

Fingolimod after natalizumab and the risk of short-term relapse

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

EDMUS, a European database for multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

Levels of evidence: Taking Neurology to the next level.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4763805

10.1212/WNL.0000000000002395

20 September 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26826205%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference